Enzymes involved in the bioconversion of ester-based prodrugs

Journal of Pharmaceutical Sciences

Volumn 95, Issue 6, 2006, Pages 1177-1195

  Liederer, Bianca M ^a   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Bioconversion; Enzyme; Esterase; Prodrug; Stability

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE; BAMBUTEROL; CAPECITABINE; CARBOXYLESTERASE; CHOLINESTERASE; COUMARIN; CYTOCHROME P450; DIPIVEFRINE; ESTER; HUMAN SERUM ALBUMIN; HYDROLASE; IRINOTECAN; ISOSORBIDE DERIVATIVE; ISOSORBIDE DIASPIRINATE; METHYLPREDNISOLONE ACETATE; MEVINOLIN; OLMESARTAN; PACLITAXEL 2 ETHYLCARBONATE; PACLITAXEL DERIVATIVE; PRODRUG; PROPRANOLOL DERIVATIVE; PRULIFLOXACIN; SIMVASTATIN; UNCLASSIFIED DRUG; VALACICLOVIR;

BINDING SITE; CATALYSIS; CHEMICAL STRUCTURE; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; NONHUMAN; SHORT SURVEY; SPECIES DIFFERENCE; STEREOCHEMISTRY;

EID: 33745031316     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20542     Document Type: Review

References (163)

1. Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, Whang B. 2004. Biotechnology: Pharmaceutical aspects. Pharmaceutical profiling in drug discovery for lead selection. Arlington, VA: AAPS Press.
2. Han HK, Amidon GL. 2000. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2:E6.
3. Majumdar S, Duvvuri S, Mitra AK. 2004. Membrane transporter/receptor- targeted prodrug design: Strategies for human and veterinary drug development. Adv Drug Deliv Rev 56:1437-1452.
4. Ettmayer P, Amidon GL, Clement B, Testa B. 2004. Lessons learned from marketed and investigational prodrugs. J Med Chem 47:2393-2404.
5. Beaumont K, Webster R, Gardner I, Dack K. 2003. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 4:461-485.
6. Rooseboom M, Commandeur JN, Vermeulen NP. 2004. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53-102.
7. Stella VJ, Charman WN, Naringrekar VH. 1985. Prodrugs. Do they have advantages in clinical practice? Drugs 29:455-473.
8. Testa B. 2004. Prodrug research: Futile or fertile? Biochem Pharmacol 68:2097-2106.
9. Albert A. 1958. Chemical aspects of selective toxicity. Nature 182:421-422.
10. Williams FM. 1985. Clinical significance of esterases in man. Clin Pharmacokinet 10:392-403.
11. White JS, White DC. 1997. Source book of enzymes. New York: CRC Press LLC.
12. Gangwar S, Pauletti GM, Wang B, Siahaan TJ, Stella VJ, Borchardt RT. 1997. Prodrug strategies to enhance the intestinal absorption of peptides. DDT 2:148-155.
13. Wang W, Jiang J, Ballard CE, Wang B. 1999. Prodrug approaches to the improved delivery of peptide drugs. Curr Pharm Des 5:265-287.
14. Liederer BM, Borchardt RT. 2005. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J Pharm Sci 94:2198-2206.
15. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T. 1995. Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 23:1022-1027.
16. Draganov DI, La Du BN. 2004. Pharmacogenetics of paraoxonases: A brief review. Naunyn Schmiedebergs Arch Pharmacol 369:78-88.
17. Ngawhirunpat T, Kawakami N, Hatanaka T, Kawakami J, Adachi I. 2003. Age dependency of esterase activity in rat and human keratinocytes. Biol Pharm Bull 26:1311-1314.
18. Moser VC, Chanda SM, Mortensen SR, Padilla S. 1998. Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol Sci 46:211-222.
19. http://www.chem.qmul.ac.uk/iubmb/enzyme/.
20. Mackness MI, Thompson HM, Hardy AR, Walker CH. 1987. Distinction between 'A'-esterases and arylesterases. Implications for esterase classification. Biochem J 245:293-296.
21. Bergmann F, Segal R, Rimon S. 1957. A new type of esterase in hog-kidney extract. Biochem J 67:481-486.
22. Aldrige WN. 1952. Serum esterases. Biochem J 53:110-117.
23. Walker CH, Mackness MI. 1983. Esterases: Problems of identification and classification. Biochem Pharmacol 32:3265-3269.
24. Satoh T, Hosokawa M. 1998. The mammalian carboxylesterases: From molecules to functions. Annu Rev Pharmacol Toxicol 38:257-288.
25. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat Struct Mol Biol 11:412-419.
26. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. 1995. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 92:7187-7191.
27. Augustinsson KB. 1964. Arylesterases. J Histochem Cytochem 12:744-747.
28. Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnson BJ, Lenz DE, Cerasoli DM. 2004. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim Biophys Acta 1702:67-77.
29. Gonzalvo MC, Gil F, Hernández AT, Villanueva E, Pla A. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105:169-179.
30. La Du BN. 1992. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc., pp 51-91.
31. Nakanishi M, Takanami Y, Maruyama T, Murata M, Motohashi Y, Nakano S, Uchida K, Maruyama C, Kyotani S, Tsushima M. 2003. The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192). J Atheroscler Thromb 10:337-342.
32. Costa LG, Cole TB, Jarvik GP, Furlong CE. 2003. Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54:371-392.
33. Durrington PN, Mackness B, Mackness MI. 2001. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480.
34. Mackness MI, Mackness B, Durrington PN. 2002. Paraoxonase and coronary heart disease. Atheroscler Suppl 3:49-55.
35. Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS. 2004. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci USA 101:482-487.
36. Eckerson HW, Wyte CM, La Du BN. 1983. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35:1126-1138.
37. Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A. 1998. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 26:355-359.
38. James RW, Deakin SP. 2004. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 37:1986-1994.
39. Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. 1998. Human liver paraoxonase (PON1): Subcellular distribution and characterization. J Biochem Mol Toxicol 12:61-69.
40. Rodrigo L, Hernandez AF, Lopez-Caballero JJ, Gil F, Pla A. 2001. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 137:123-137.
41. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. 1994. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33:832-839.
42. Biggadike K, Angell RM, Burgess CM, Farrell RM, Hancock AP, Harker AJ, Irving WR, Ioannou C, Procopiou PA, Shaw RE, Solanke YE, Singh OM, Snowden MA, Stubbs RJ, Walton S, Weston HE. 2000. Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism. J Med Chem 43:19-21.
43. Satoh T, Hosokawa M. 1995. Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicol Lett 82-83:439-445.
44. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. 1991. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science 253:872-879.
45. Taylor P, Radic Z. 1994. The cholinesterases: From genes to proteins. Annu Rev Pharmacol Toxicol 34:281-320.
46. Bencharit S, Morton CL, Hyatt JL, Kuhn P, Danks MK, Potter PM, Redinbo MR. 2003. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition. Chem Biol 10:341-349.
47. Stok JE, Goloshchapov A, Song C, Wheelock CE, Derbel MB, Morisseau C, Hammock BD. 2004. Investigation of the role of a second conserved serine in carboxylesterases via site-directed mutagenesis. Arch Biochem Biophys 430:247-255.
48. Liu P, Wang YF, Ewis HE, Abdelal AT, Lu CD, Harrison RW, Weber IT. 2004. Covalent reaction intermediate revealed in crystal structure of the Geobacillus stearothermophilus carboxylesterase Est30. J Mol Biol 342:551-561.
49. Harel M, Quinn DM, Nair HK, Silman I, Sussman JL. 1996. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J Am Chem Soc 118:2340-2346.
50. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. 2003. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278:41141-41147.
51. Wheelock CE, Severson TF, Hammock BD. 2001. Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility. Chem Res Toxicol 14:1563-1572.
52. Shinotoh H, Fukushi K, Nagatsuka S, Irie T. 2004. Acetylcholinesterase imaging: Its use in therapy evaluation and drug design. Curr Pharm Des 10:1505-1517.
53. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. 1993. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog Brain Res 98:431-438.
54. Voisin T, Reyǹish E, Portet F, Feldman H, Vellas B. 2004. What are the treatment options for patients with severe Alzheimer's disease? CNS Drugs 18:575-583.
55. Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, Beroza P, Danks MK, Potter PM. 2004. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 65:1336-1343.
56. Bourland JA, Martin DK, Mayersohn M. 1997. Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: Preliminary in vitro findings using a rat liver preparation. J Pharm Sci 86:1494-1496.
57. Sato T, Moroi K. 1971. Species and age differences in the activity of isocarboxazid hydrolysing enzyme. Arch Int Pharmacodyn Ther 192:128-134.
58. Sogorb MA, Vilanova E. 2002. Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis. Toxicol Lett 128:215-228.
59. Zhen L, Rusiniak ME, Swank RT. 1995. The beta-glucuronidase propeptide contains a serpin-related octamer necessary for complex formation with egasyn esterase and for retention within the endoplasmic reticulum. J Biol Chem 270:11912-11920.
60. Macintyre S, Samols D, Dailey P. 1994. Two carboxylesterases bind C-reactive protein within the endoplasmic reticulum and regulate its secretion during the acute phase response. J Biol Chem 269:24496-24503.
61. Leinweber FJ. 1987. Possible physiological roles of carboxylic ester hydrolases. Drug Metab Rev 18:379-439.
62. Heyman E. 1980. Carboxylesterases and amidases. In: Jacoby WB, editor. Enzymatic basis of detoxification. New York: Academic Press, Inc., pp 291-323.
63. Satoh T. 1987. Role of carboxylesterases in xenobiotic metabolism. In: Benda JR, Hodgson BE, Philpot R, editors. Reviews in biochemical toxicology. New York: Elsevier, pp 155-181.
64. Quinn DM. 1987. Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states. Chem Rev 87:955-979.
65. Udata C, Tirucherai G, Mitra AK. 1999. Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs. J Pharm Sci 88:544-550.
66. Tak RV, Pal D, Gao H, Dey S, Mitra AK. 2001. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J Pharm Sci 90:1505-1515.
67. Crauste-Manciet S, Decroix M, Farinotti R, Chaumeil J. 1997. Cefpodoxime-proxetil hydrolysis and food effects in the intestinal lumen before absorption: In vitro comparison of rabbit and human material. Int J Pharm 157:153-161.
68. Soreq H, Seidman S. 2001. Acetylcholinesterase- new roles for an old actor. Nat Rev Neurosci 2:294-302.
69. Sklan EH, Lowenthal A, Korner M, Ritov Y, Landers DM, Rankinen T, Bouchard C, Leon AS, Rice T, Rao DC, Wilmore JH, Skinner JS, Soreq H. 2004. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study. Proc Natl Acad Sci USA 101:5512-5517.
70. Fuhrman B, Partoush A, Aviram M. 2004. Acetylcholine esterase protects LDL against oxidation. Biochem Biophys Res Commun 322:974-978.
71. Rotundo RL. 2003. Expression and localization of acetylcholinesterase at the neuromuscular junction. J Neurocytol 32:743-766.
72. Massoulié J. 2000. Molecular forms and anchoring of acetylcholinesterase. In: Giacobini E, editor. Cholinesterases and cholinesterases inhibitors. London: Martin Dunitz, pp 81-101.
73. Kamanyire R, Karalliedde L. 2004. Organophosphate toxicity and occupational exposure. Occup Med (Lond) 54:69-75.
74. Vellom DC, Radic Z, Li Y, Pickering NA, Camp S, Taylor P. 1993. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry 32:12-17.
75. Massoulie J. 2002. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 11:130-143.
76. Lockridge O. 1992. Genetic variants of human serum butyrylcholinesterase influence the metabolism of the muscle relaxant succinylcholine. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc., pp 15-50.
77. Jarvinen T, Poikolainen M, Suhonen P, Vepsalainen J, Alaranta S, Urtti A. 1995. Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea, and butyrylcholinesterase solutions. J Pharm Sci 84:656-660.
78. Gilmer JF, Moriarty LM, Lally MN, Clancy JM. 2002. Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate. Eur J Pharm Sci 16:297-304.
79. Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FM. 1993. Molecular and cellular biology of cholinesterases. Prog Neurobiol 41:31-91.
80. Massoulié J, Anselmet A, Bon S, Krejci E, Lagay C, Mayat E, Morel N, Simon S. 1998. Diversity and processing of acetylcholinesterase. In: Doctor BP, Quinn DM, Rotundo RL, Taylor P, editors. Structure and function of cholinesterases and related proteins. New York: Plenum Press.
81. Massoulié J, Anselmet A, Bon S, Krejci E, Legay C, Morel N, Simon S. 1998. Acetylcholinesterase: C-terminal domains, molecular forms and functional localization. J Physiol Paris 92:183-190.
82. Brimijoin S. 1983. Molecular forms of acetylcholinesterase in brain, nerve and muscle: Nature, localization and dynamics. Prog Neurobiol 21:291-322.
83. Massoulié J, Bon S. 1982. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu Rev Neurosci 5:57-106.
84. Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. 2003. Identification of a human valacyclovirase: Biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 278:25348-25356.
85. Parkinson A. 2001. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarett & Doull's Toxicology: The basic science of poisons, 6th edn. New York: McGraw-Hill Professionals.
86. Gil F, Pla A, Gonzalvo MC, Hernández AF, Villanueva E. 1993. Rat liver paraoxonase: Subcellular distribution and characterization. Chem Biol Interact 87:149-154.
87. Holmes RS, Masters CJ. 1967. A comparative study of the multiplicity of mammalian esterases. Biochimica et Biophysica Acta 151:147-158.
88. Massoulié J. 2000. Molecular forms and anchoring of acetylcholinesterase. In: Giacobini E, editor. Cholinesterases and cholinesterases inhibitors. London: Martin Dunitz, pp 81-101.
89. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF. 2004. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1 -amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 32:505-511.
90. Kalow W, Bertilsson L. 1994. Interethnic factors affecting drug response. Adv Drug Res 25:1-53.
91. Stampfli HF, Quon CY. 1995. Polymorphic meteabolism of flestolol and other ester containing compounds by a carboxylesterase in new zealand white rabbit blood and cornea. Res Commun Mol Pathol Pharmacol 88:87-97.
92. Ketterman AJ. 1991. Polymorphisms of human liver carboxylesterases. Biochem Soc Trans 19:306S.
93. Melton RG, Knox RJ. 1999. Enzyme-prodrug strategies for cancer therapy. New York: Kluwer Academic/Plenum Publisher.
94. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. 1998. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281.
95. Kerr DJ, Young LS, Searle PF, McNeish IA. 1997. Gene directed enzyme prodrug therapy for cancer. Adv Drug Deliv Rev 26:173-184.
96. Denny WA. 2003. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003:48-70.
97. Xu G, McLeod HL. 2001. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 7:3314-3324.
98. Wade LA, Katzman R. 1975. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem 25:837-842.
99. Salvi A, Carrupt PA, Mayer JM, Testa B. 1997. Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid. Drug Metab Dispos 25:395-398.
100. Sakurai Y, Ma SF, Watanabe H, Yamaotsu N, Hirono S, Kurono Y, Kragh-Hansen U, Otagiri M. 2004. Esterase-like activity of serum albumin: Characterization of its structural chemistry using p-nitrophenyl esters as substrates. Pharm Res 21:285-292.
101. Laethem RM, Blumenkopf TA, Cory M, Elwell L, Moxham CP, Ray PH, Walton LM, Smith GK. 1996. Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2. Arch Biochem Biophys 332:8-18.
102. Auld DS, Holmquist B. 1974. Carboxypeptidase A. Differences in the mechanisms of ester and peptide hydrolysis. Biochemistry 13:4355-4361.
103. Sidhu RS, Blair AH. 1975. Human liver aldehyde dehydrogenase. Esterase activity. J Biol Chem 250:7894-7898.
104. Yoshida A, Rzhetsky A, Hsu LC, Chang C. 1998. Human aldehyde dehydrogenase gene family. Eur J Biochem 251:549-557.
105. Verpoorte JA, Mehta S, Edsall JT. 1967. Esterase activities of human carbonic anhydrases B and C. J Biol Chem 242:4221-4229.
106. Tsujita T, Shirai K, Saito Y, Okuda H. 1990. Relationship between lipase and esterase. Prog Clin Biol Res 344:915-933.
107. Tsunematsu H, Yoshida S, Horie K, Yamamoto M. 1995. Synthesis and the stereoselective enzymatic hydrolysis of flurbiprofen-basic amino acid ethyl esters. J Drug Target 6:517-525.
108. Oosterhoff D, Witlox MA, van Beusechem VW, Haisma HJ, Schaap GR, Bras J, Kruyt FA, Molenaar B, Boven E, Wuisman PI, Pinedo HM, Gerritsen WR. 2003. Gene-directed-enzyme prodrug therapy for osteosarcoma: Sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol Cancer Ther 2:765-771.
109. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:647-653.
110. Danks MK, Potter PM. 2003. Enzyme-prodrug systems. In: Springer CJ, editor. Suicide gene therapy: Methods and reviews. Totowa: Humana Press Inc., pp 247-262.
111. Hosokawa M, Maki T, Satoh T. 1990. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch Biochem Biophys 277:219-227.
112. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. 1994. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664.
113. Yoshigae Y, Imai T, Horita A, Matsukane H, Otagiri M. 1998. Species differences in stereoselective hydrolase activity in intestinal mucosa. Pharm Res 15:626-631.
114. McCracken NW, Blain PG, Williams FM. 1993. Human xenobiotic metabolizing esterases in liver and blood. Biochem Pharmacol 46:1125-1129.
115. Yang JZ, Chen W, Borchardt RT. 2002. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J Pharmacol Exp Ther 303:840-848.
116. Mahmood I. 1999. Allometric issues in drug development. J Pharm Sci 88:1101-1106.
117. Jang GR, Harris RZ, Lau DT. 2001. Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev 21:382-396.
118. Bonate PL, Howard D. 2000. Prospective allometric scaling: Does the emperor have clothes? J Clin Pharmacol 40:665-670; discussion 671-676.
119. Muller F, Dumez Y, Massoulié J. 1985. Molecular forms and solubility of acetylcholinesterase during the embryonic development of rat and human brain. Brain Res 331:295-302.
120. Arendt T, Brückner MK, Lange M, Bigl V. 1992. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem Int 21:381-396.
121. Younkin SG, Goodridge B, Katz J, Lockett G, Nafziger D, Usiak MF, Younkin LH. 1986. Molecular forms of acetylcholinesterases in Alzheimer's disease. Fed Proc 45:2982-2988.
122. Schegg KM, Nielsen S, Zweig RM, Peacock JH. 1989. Decrease in membrane-bound G4 form of acetylcholinesterase in postmortem Alzheimer brain. Prog Clin Biol Res 317:437-452.
123. Talesa VN. 2001. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 122:1961-1969.
124. Van Gelder J, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. 1999. Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: An in vitro study. Pharm Res 16:1035-1040.
125. Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. 2000. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 28:1394-1396.
126. Meshorer E, Erb C, Gazit R, Pavlovsky L, Kaufer D, Friedman A, Glick D, Ben-Arie N, Soreq H. 2002. Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science 295:508-512.
127. Gisiger V, Sherker S, Gardiner PF. 1991. Swimming training increases the G4 acetylcholinesterase content of both fast ankle extensors and flexors. FEBS Lett 278:271-273.
128. Jasmin BJ, Gisiger V. 1990. Regulation by exercise of the pool of G4 acetylcholinesterase characterizing fast muscles: Opposite effect of running training in antagonist muscles. J Neurosci 10:1444-1454.
129. Tuovinen K, Kaliste-Korhonen E, Hänninen O. 1997. Gender differences in activities of mouse esterase and sensitivities to DFP and sarin toxicity. Gen Pharmacol 29:333-335.
130. Brass EP, Mayer MD, Mulford DJ, Stickler TK, Hoppel CL. 2003. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin Pharmacol Ther 73:338-347.
131. Simon V, Resnick E. 2004. Drug therapy and gender. US Pharm 29:37-38.
132. Mork N, Bundgaard H. 1992. Stereoselective enzymatic hydrolysis of various ester prodrugs of ibuprofen and flurbiprofen in human plasma. Pharm Res 9:492-496.
133. Stoeckel K, Hofheinz W, Laneury JP, Duchene P, Shedlofsky S, Blouin RA. 1998. Stability of cephalosporin prodrug esters in human intestinal juice: Implications for oral bioavailability. Antimicrob Agents Chemother 42:2602-2606.
134. Hong SY, Oh JE, Lee KH. 1999. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58:1775-1780.
135. Burke D, Henderson DJ. 2002. Chirality: A blueprint for the future. Br J Anaesfch 88:563-576.
136. Islam MR, Mahdi JG, Bowen ID. 1997. Pharmacological importance of stereochemical resolution of enantiomeric drugs. Drug Saf 17:149-165.
137. Hutt AJ, O'Grady J. 1996. Drug, chirality: A consideration of the significance of the stereochemistry of antimicrobial agents. J Antimicrob Chemother 37:7-32.
138. Hayball PJ. 1996. Chirality and nonsteroidal antiinflammatory drugs. Drugs 52:47-58.
139. Hutt AJ, Tan SC. 1996. Drug chirality and its clinical significance. Drugs 52:1-12.
140. Zych LA, Yang W, Liao Y, Griffin KR, Wang B. 2004. The effect of substitution patterns on the release rates of opioid peptides DADLE and [Leu(5)]-enkephalin from coumarin prodrug moieties. Bioorg Chem 32:109-123.
141. Wadkins RM, Morton CL, Weeks JK, Oliver L, Wierdl M, Danks MK, Potter PM. 2001. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol 60:355-362.
142. Buchwald P, Bodor N. 1999. Quantitative structure-metabolism relationships: Steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 42:5160-5168.
143. Senter PD, Marquardt H, Thomas BA, Hammock BD, Frank IS, Svensson HP. 1996. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res 56:1471-1474.
144. Morton CL, Wadkins RM, Danks MK, Potter PM. 1999. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59:1458-1463.
145. Yoshigae Y, Imai T, Taketani M, Otagiri M. 1999. Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma. Chirality 11:10-13.
146. Burnette TC, Harrington JA, Reardon JE, Merrill BM, de Miranda P. 1995. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 270:15827-15831.
147. Tunek A, Levin E, Svensson LA. 1988. Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem Pharmacol 37:3867-3876.
148. Meyers C, Lockridge O, La Du BN. 1982. Hydrolysis of methylprednisolone acetate by human serum cholinesterase. Drug Metab Dispos 10:279-280.
149. Nakamura M, Shirasawa E, Hikida M. 1993. Characterization of esterases involved in the hydrolysis of dipivefrin hydrochloride. Ophthalmic Res 25:46-51.
150. Laeis P, Puchler K, Kirch W. 2001. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 19:S21-S32.
151. Yan B, Matoney L, Yang D. 1999. Human carboxylesterases in term placentae: Enzymatic characterization, molecular cloning and evidence for the existence of multiple forms. Placenta 20:599-607.
152. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. 1986. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 47:263-277.
153. Hutchins JB, Bernanke JM, Jefferson VE. 1995. Acetylcholinesterase in the developing ferret retina. Exp Eye Res 60:113-125.
154. Berninsone P, Katz E, Napp M, Azcurra J. 1989. Acetylcholinesterase and nonspecific cholinesterase activities in rat liver: Subcellular localization, molecular forms, and some extraction properties. Biochem Cell Biol 67:817-822.
155. Sanchez-Chavez G, Vidai CJ, Salceda R. 1995. Acetyl- and butyrylcholinesterase activities in the rat retina and retinal pigment epithelium. J Neurosci Res 41:655-662.
156. Hahn T, Desoye G, Lang I, Skofitsch G. 1993. Location and activities of acetylcholinesterase and butyrylcholinesterase in the rat and human placenta. Anat Embryol (Berl) 188:435-440.
157. Sine JP, Ferrand R, Colas B. 1988. Acetylcholinesterase and butyrylcholinesterase in the gut mucosal cells of various mammal species: Distribution along the intestine and molecular forms. Comp Biochem Physiol C 91:597-602.
158. Vainio H. 1980. Role of hepatic metabolism. In: Testa B, Jenner P, editors. Concepts in drug metabolism. New York: Marcel Decker, Inc., pp 251-284.
159. Ling G, Gu J, Genter MB, Zhuo X, Ding X. 2004. Regulation of cytochrome P450 gene expression in the olfactory mucosa. Chem Biol Interact 147:247-258.
160. Syme MR, Paxton JW, Keelan JA. 2004. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487-514.
161. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H, Kawamoto T. 2004. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9:1967-1976.
162. Duvvuri S, Majumdar S, Mitra AK. 2004. Role of metabolism in ocular drug delivery. Curr Drug Metab 5:507-515.
163. Patterson LH, Murray GI. 2002. Tumour cytochrome P450 and drug activation. Curr Pharm Des 8:1335-1347.